Skip to main content
SpringerLink
Log in

Micrometastatic bone marrow involvement: detection and prognostic significance

  • Review
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The present review focuses on the methodology and clinical significance of new diagnostic approaches to identify individual cancer cells present in bone marrow, both as a frequent site of metastasis formation and an indicator organ for hematogenous tumor cell dissemination. The steadily increasing number of studies on this issues is characterized by considerable methodological variations of important variables, such as the size of the study population, and the reliability of monoclonal antibodies used for tumor cell detection. Emerging data indicate that this disturbing heterogeneity might be overcome by the use of reliable and specific anti-cytokeratin antibodies (for example, A45-B/B3) as, for the time, standard markers for the detection of micrometastatic tumor cells in bone marrow. Prospective clinical studies have shown that immunoassays based on anti-CK antibodies identify patients’ subgroups with a poor clinical prognosis with regard to early metastasis manifestation and reduced overall survival in various epithelial tumor entities, including breast, colon, rectum, stomach, esophagous, prostate, renal, blasdder, and nonsmall cell lung cancer. The immunocytochemical assays may be therefore used to improve tumor staging with potential consequences for adjuvant therapy, because disseminated cells appeared to be dormant, non-cycling (for example Ki-67 antigen-negative) cells, suggesting a resistance to cell-cycle dependent therapy, such as chemotherapy. Therefore, cell-cycle independent antibody-based immunotherapy might be an interesting option to complement chemotherapy. Another promising clinical application is monitoring the response of micrometastatic cells to adjuvant therapies, which, at present, can only be assessed retrospectively after an extended period of clinical followup. The outlined current strategies for detection and characterization of cancer micrometastasis might help to design and control new therapeutic strategies for secondary prevention of metastatic relapse in patients with operable primary carcinomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990.Eur J Cancer 1997;33: 1075–1107.

    Article  CAS  PubMed  Google Scholar 

  2. Pantel K. Detection of minimal disease in patients with solid tumors.J Hematother 1996;5: 359–367.

    Article  CAS  PubMed  Google Scholar 

  3. Fidler IJ, Radinsky R. Genetic control of cancer metastasis.J Natl Cancer Inst 1990;82: 166–168.

    Article  CAS  PubMed  Google Scholar 

  4. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.Cell 1991;64: 327–336.

    Article  CAS  PubMed  Google Scholar 

  5. Schlimok Get al. Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies.Proc Natl Acad Sci USA 1987;84: 8672–8676.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Mansi JLet al. Micrometastasis in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastasis.Br Med J 1987;295: 1093–1096.

    Article  CAS  Google Scholar 

  7. Braun S, Pantel K. Prognostic significance of micrometastatic bone marrow involvement.Breast Cancer Res Treat 1998;52: 201–216.

    Article  CAS  PubMed  Google Scholar 

  8. Pantel Ket al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells.J Natl Cancer Inst 1993;85: 1419–1424.

    Article  CAS  PubMed  Google Scholar 

  9. Slamon JDet al. Addition of HerceptinTM (humanized anti-HER2 antibody) to first-line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anti-cancer activity: a randomized, multinational controlled phase III trial.Proc American Society of Oncology 1998;17: 98 (abstr 377.)

    Google Scholar 

  10. Baselga Jet al. Phase II study of weekly intravenous recombinant humanized anti-p 185Her2 monoclonal antibody in patients with Her2/neu-overexpressing metastatic breast cancer.J Clin Oncol 1996;14: 737–744.

    Article  CAS  PubMed  Google Scholar 

  11. Riethmüller Get al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma.Lancet 1994;343: 1177–1183.

    Article  PubMed  Google Scholar 

  12. Salvadori Bet al. Use of monoclonal antibody MBrl to detect micrometastasis in bone marrow specimens of breast cancer patients.Eur J Cancer 1990;26: 865–867.

    Article  CAS  PubMed  Google Scholar 

  13. Courtemanche DJ, Worth AJ, Coupland RW, Rowell JL, MacFarlane JK. Monoclonal antibody LICR-LON-M8 does not predict the outcome of operable breast cancer.Can J Surg 1991;34: 21–26.

    CAS  PubMed  Google Scholar 

  14. Mathieu MCet al. Immunohistochemical staining of bone marrow biopsies for detection of occult metastsis in breast cancer.Breast Cancer Res Treat 1990;15: 21–26.

    Article  CAS  PubMed  Google Scholar 

  15. Mansi JLet al. Bone marrow micrometastasis in primary breast cancer: prognostic significance after 6 years follow-up.Eur J Cancer 1991;27: 1552–1555.

    Article  CAS  PubMed  Google Scholar 

  16. Gogas H, Mansi JL, Bliss J, Coomes RC. Can the presence of micrometastasis in primary breast cancer predict outcome? Long-term (median 12.5 yrs) follow-up.Proc American Society of Oncology 1997;16: 153a (abstract #537).

    Google Scholar 

  17. Kirk SJet al. The prognostic significance of marrow micrometastasis in women with early breast cancer.Eur J Surg Oncol 1990;16: 481–485.

    CAS  PubMed  Google Scholar 

  18. Harbeck N, Untch M, Pache L, Eiermann W. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up.Br J Cancer 1994;69: 566–571.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Diel IJet al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.J Natl Cancer Inst 1996;88: 1652–1664.

    Article  CAS  PubMed  Google Scholar 

  20. Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastasis.J Clin Oncol 1991;9: 1749–1756.

    Article  CAS  PubMed  Google Scholar 

  21. Singletary SE, Larry L, Trucker SL Spitzer G. Detection of micrometastatic tumor cells in bone marrow of breast carcinoma patients.J Surg Oncol 1991;47: 32–36.

    Article  CAS  PubMed  Google Scholar 

  22. Schlimok G.et al. Prognostic significance of disseminated tumor cells detected in bone marrow of patients with breast and colorectal cancer: a multivariate analysis.Proc Am Soc Clin Oncol 1992;11: 102 (abstract).

    Google Scholar 

  23. Braun Set al. Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.J Natl Cancer Inst 1998;90: 1099–1100.

    Article  CAS  PubMed  Google Scholar 

  24. Sloane JP. Molecules and micrometastasis.Lancet 1995;345: 1255–1256.

    Article  CAS  PubMed  Google Scholar 

  25. Pantel Ket al. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow.J Hematother 1994;3: 165–173.

    Article  CAS  PubMed  Google Scholar 

  26. Mansi JL, Berger U, Wilson P, Shearer R, Coombes RC. Detection of tumor cells in bone marrow of patients with prostatic carcinoma by immunocytochemical techniques.J Urology 1988;139: 545–548.

    Article  CAS  Google Scholar 

  27. Pantel Ket al. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with nonsmall cell lung cancer without overt metastasis.Lancet 1996;347: 649–653.

    Article  CAS  PubMed  Google Scholar 

  28. Schlimok Get al. Epithelial tumor cells in bone marrow of patients with colorectal cancer: immunocytochemical detection, phenotypic characterization, and prognostic significance.J Clin Oncol 1990;8: 831–837.

    Article  CAS  PubMed  Google Scholar 

  29. Braun S, Pantel K. Biological characteristics of micrometastatic carcinoma cells in bone marrow. In: Günthert U, Birchmeier W, (eds).Attempts to understand metastasis formation. Berlin-New York-Tokyo: Springer, 1996:Curr Top Microbiol Immunol: vol 213/I), pp 163–177.

    Chapter  Google Scholar 

  30. Gallee MPWet al. Characterization of monoclonal antibodies raised against prostatic cell line PC-82.Prostate 1986;9: 33–45.

    Article  CAS  PubMed  Google Scholar 

  31. Osborne Met al. Sensitivity of immunocytochemical detection of breast cancer cells in human bone marrow.Cancer Res 1991;51: 2706–2609.

    CAS  PubMed  Google Scholar 

  32. Molino Aet al. A comparative analysis of three different techniques for the detection of breast cancer cells in bone marrow.Cancer 1991;67: 1033–1036.

    Article  CAS  PubMed  Google Scholar 

  33. Jauch KWet al. Prognostic significance of bone marrow micrometastasis in patients with gastric cancer.J Clin Oncol 1996;14: 1810–1817.

    Article  CAS  PubMed  Google Scholar 

  34. Diel IJet al. Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis.J Clin Oncol 1992;10: 1534–1539.

    Article  CAS  PubMed  Google Scholar 

  35. Schwarz G. Cytomorphology and cell yield in a new cytocentrifugal technique allowing the collection of the cell-free supernatnat.Lab Med 1991;15: 45–50.

    Google Scholar 

  36. Gribben JG, Freedman AS, Neuberg D. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation of B-cell lymphoma.N Engl J Med. 1991;325: 1525–1533.

    Article  CAS  PubMed  Google Scholar 

  37. Bos IL. Ras oncogenes in human cancer: a review.Cancer Res 1989;49: 4682–4689.

    CAS  PubMed  Google Scholar 

  38. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene.N Engl J Med 1993;329: 1318–1327.

    Article  CAS  PubMed  Google Scholar 

  39. Hayashi Net al. Genetic diagnosis identifies occult lymph node metastasis undetectable by the histopathological method.Cancer Res 1994;54: 3853–3856.

    CAS  PubMed  Google Scholar 

  40. Hayashi Net al. Genetic diagnosis of lymph-node metastasis in colorectal cancer.Lancet 1995;345: 1257–1259.

    Article  CAS  PubMed  Google Scholar 

  41. Datta YH, Adams PT, Drobyski WR. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction.J Clin Oncol 1994;12: 475–482.

    Article  CAS  PubMed  Google Scholar 

  42. Wood DP, Jr., Banks ER, Humphreys S, Rangnekar VM. Sensitivity of immunohistochemistry and polymerase chain reaction in detecting prostate cancer cells in bone marrow.J Histochem Cytochem 1994;42: 505–511.

    Article  CAS  PubMed  Google Scholar 

  43. Zippelius Aet al. Limitations of reverse transcriptase-polymerase chain reaction for detection of micrometastatic epithelial cancer cells in bone marrow.J Clin Oncol 1997;15: 2701–2708.

    Article  CAS  PubMed  Google Scholar 

  44. Soeth Eet al. Comprative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using RT-PCR.Cancer Res 1997;57: 3106.

    CAS  PubMed  Google Scholar 

  45. Gerhard Met al. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction.J Clin Oncol 1994;12: 725–729.

    Article  CAS  PubMed  Google Scholar 

  46. De Graaf H, Maelandssmo GM, Ruud Pet al. Ectopic expression of target genes may represent an inherent limitation of RT-PCR assays used for micrometastasis detection: studies on the epithelial glycoprotein gene EGP-2.Int J Cancer 1997;722: 191–196.

    Article  Google Scholar 

  47. Krismann Met al. Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination.J Clin Oncol 1995;13: 2769–2775.

    Article  CAS  PubMed  Google Scholar 

  48. Schoenfeld Aet al. Detection of breast cancer micrometastasis in axillary lymph nodes by using Polymerase Chain Reaction.Cancer Res 1994;54: 2986–2990.

    CAS  PubMed  Google Scholar 

  49. Traweek ST, Liu J, Battifora H. Keratin gene expression in non-epithelial tissues. Detection with polymerase chain reaction.Am J Pathol 1993;142: 1111–1118.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Fields KKet al. Clinical significance of bone marrow metastasis as detected using polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation.J Clin Oncol 1996;14: 1868–1876.

    Article  CAS  PubMed  Google Scholar 

  51. Pantel Ket al. Association of cytokeratin-positive breast cancer micrometastasis with early recurrence and poor overall survival.Proc American Society of Clinical Oncology 1998;17: 165a (abstr 633).

    Google Scholar 

  52. Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmüller G. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients.Lancet 1992;340: 685–689.

    Article  CAS  PubMed  Google Scholar 

  53. Juhl Het al. Immunocytological detection of micrometastatic cells: Comparative evaluation of findings in the peritoneal cavity and the bone marrow of gastric, colorectal and pancreatic cancer patients.Int J Cancer 1994;57: 330–335.

    Article  CAS  PubMed  Google Scholar 

  54. Schlimok Get al. Micrometastatic tumor cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance.Eur J Cancer 1991;27: 1461–1465.

    Article  CAS  PubMed  Google Scholar 

  55. Funke Iet al. Comparative analyses of bone marrow micro-metastasis in breast and gastric cancer.In J Cancer 1996;65: 755–761.

    CAS  Google Scholar 

  56. Thorban Set al. Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma.J Natl Cancer Inst 1996;88: 1222–1227.

    Article  CAS  PubMed  Google Scholar 

  57. Oberneder Ret al. Prognostic relevance of micrometastatic tumor cells in bone marrow of patients with genitourinary tract tumors.J Urol 1994;151: 413A (abstract).

    Google Scholar 

  58. Riesenberg Ret al. Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumor cells.Histochem 1993;99: 61–66.

    Article  CAS  Google Scholar 

  59. Braun S, Hepp, F, Janni W, Blankenstein T, Pantel K. Occult tumor cells immunocytochemically identified in bone marrow of patients with apparently localized ovarian cancer predict early distant metastatic relapse, 1999;submitted.

  60. Kamby Ket al. The presence of tumor cell in bone marrow at the time of first recurrence of breast cancers.Cancer 1987;60: 1306–1312.

    Article  CAS  PubMed  Google Scholar 

  61. Berger Uet al. The relationship between micrometastasis in the bone marrow, histopathologic features of the primary tumor in breast cancer and prognosis.Am J Clin Pathol 1988;90: 1–6.

    Article  CAS  PubMed  Google Scholar 

  62. Cote RJet al. Monoclonal antibodies detect occult breast carcinoma metastasis in the bone marrow of patients with early stage disease.Am J Surg Pathol 1988;12: 333–340.

    Article  CAS  PubMed  Google Scholar 

  63. Taylor-Papadimitriou J, Burchell J, Moss F, Beverly P. Monoclonal antibodies to epithelial membrane antigen and human milk fat globule mucin define epitopes expressed on other molecules.Lancet 1985;1: 458.

    Article  CAS  PubMed  Google Scholar 

  64. Heyderman E, Macartney JC. Epithelial membrane antigen and lymphoid cells.Lancet 1985;1: 109.

    Article  Google Scholar 

  65. Delsol Get al. Human lymphoid cells express epithelial membrane antigen.Lancet 1984, No. 17,2: 1124–1129.

    Article  CAS  PubMed  Google Scholar 

  66. Fox SBet al. Association of tumor angiogenesis with bone marrow micrometastasis in breast cancer.J Natl Cancer Inst 1997;89: 1044–1049.

    Article  CAS  PubMed  Google Scholar 

  67. Bonnheim DC, Petrelli NJ, Herrera L, Walsh D, Mittelman A. Osseus metastasis from colorectal carcinoma.Am J Surg 1986;151: 457–459.

    Article  CAS  PubMed  Google Scholar 

  68. Weiss Let al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies.J Pathol 1986;150: 195–203.

    Article  CAS  PubMed  Google Scholar 

  69. Welch JP, Donaldson GA. The clinical correlation of an autopsy study of recurrent colorectal cancer.Ann Surg 1979;189: 496–502.

    CAS  PubMed  PubMed Central  Google Scholar 

  70. Cannistra SA. Cancer of the ovary.N Engl J Med 1993;329: 1550–1559.

    Article  CAS  PubMed  Google Scholar 

  71. Abdul-Karim FWet al. Bone metastasis from gynecologic carcinomas: a clinicopathologic study.Gynecol Oncol 1990;39: 108–114.

    Article  CAS  PubMed  Google Scholar 

  72. Dauplat Jet al. Distant metastasis in epithelial ovarian carcinoma.Cancer 1987;60: 1561–1566.

    Article  CAS  PubMed  Google Scholar 

  73. Cain JMet al. Bone marrow involvement in epithelial ovarian cancer by immunocytochemical assessment.Gynecol Oncol 1990;38: 442–445.

    Article  CAS  PubMed  Google Scholar 

  74. Ross AAet al. Immunocytochemical detection of tumor cells in bone marrow and peripheral blood stem cell collections from patients with ovarian cancer.Bone Marrow Transplant 1995;15: 929–933.

    CAS  PubMed  Google Scholar 

  75. Pantel Ket al. Immunocytochemical monitoring of micrometastatic disease: reduction of prostate cancer cells in bone marrow by androgen deprivation.Int J Cancer 1997;71: 521–525.

    Article  CAS  PubMed  Google Scholar 

  76. Dillman RO. Antibodies as cytotoxic therapy.J Clin Oncol 1994;12; 1497–1515.

    Article  CAS  PubMed  Google Scholar 

  77. Braun S, Hepp F, Sommer HL, Pantel K. Tumor antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease.Int J Cancer 1999;84: 1–5.

    Article  CAS  PubMed  Google Scholar 

  78. Braun S, Hepp F, Janni W, Sommer HL, Pantel K. Reduction of micrometastatic tumor load by monoclonal antibody therapy: influence of tumor antigen heterogeneity.Ann Oncol 1998;9: 129 (abstr 621).

    Article  Google Scholar 

  79. Schlimok G, Pantel K, Loibner H, Fackler-Schwalbe I, Riethmüller G. Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: toward a novel surrogate test to monitor adjuvant therapies of solid tumours.Eur J Cancer 1995;31A: 1799–1803.

    Article  CAS  PubMed  Google Scholar 

  80. Scholz D, Lubeck M, Loibner H. Biological activity in the human system of isotype variants of oligosaccharide Y-specific murine monoclonal antibodies.Cancer Immunol Immunother 1991;33: 153–157.

    Article  CAS  PubMed  Google Scholar 

  81. Hempel D, Müller, P, Oruzio D, Ehnle S, Schlimok G. Adoptive immunotherapy with monoclonal antibody 17-1A to reduce minimal residual disease in breast cancer patients after high-dose chemotherapy.Blood 1997;90 (Suppl 1)379B, abstract #4454.

  82. Hohaus Set al. Persistence of isolated tumor cells in patients with breast cancer after sequential high-dose therapy with peripheral blood stem cell transplantation.Blood 1996;88 (Suppl)10: 128A (abstract 501).

    Google Scholar 

  83. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors.Cancer Res 1990;50: 2741–2451

    Google Scholar 

  84. Riethmüller G, Johnson JP. Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancer.Curr Opin Immunol 1992;4: 647–655.

    Article  PubMed  Google Scholar 

  85. Scott AM, Welt S. Antibody-based immunological therapies.Curr Opin Immunol 1997;9: 717–722.

    Article  CAS  PubMed  Google Scholar 

  86. Funke I, Schraut W. Meta-analysis of studies on bone marrow micrometastasis: An independent prognostic impact remains to be substantiated.J Clin Oncol 1998;16: 557–566.

    Article  CAS  PubMed  Google Scholar 

  87. Pantel Ket al. Establishment of micrometastatic carcinoma cell lines: a novel source of tumor cell vaccines.J Natl Cancer Inst 1995;87: 1162–1168.

    Article  CAS  PubMed  Google Scholar 

  88. Putz Eet al. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastasis.Cancer Res 1999;59: 241–248.

    CAS  PubMed  Google Scholar 

  89. Pantel K, Putz E, Riethmüller G. Identification of new therapeutic targets on bone marrow micrometastasis.Blood 1997;90, (Suppl 1): 421A (abstract 1871).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Frauenklinik, Klinikum Innenstadt, Ludwig-Maximilians-Universität, Maistrasse 11, D-80337, München, Germany

    S Braun

  2. Molekulare Diagnostik & Therapie, Universitäts-Frauenklinik, Universitätsklinikum Eppendorf, Martinistrasse 52, D-20246, Hamburg, Germany

    K Pantel

Authors
  1. S Braun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Pantel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K Pantel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Braun, S., Pantel, K. Micrometastatic bone marrow involvement: detection and prognostic significance. Med Oncol 16, 154–165 (1999). https://doi.org/10.1007/BF02906127

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02906127

Keywords

Search

Navigation